Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan.

Isobe T, Uchino K, Makiyama C, Ariyama H, Arita S, Tamura S, Komoda M, Kusaba H, Shirakawa T, Esaki T, Mitsugi K, Takaishi S, Akashi K, Baba E.

Anticancer Res. 2014 Apr;34(4):2035-40.

PMID:
24692744
2.

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy.

Österlund P, Soveri LM, Isoniemi H, Poussa T, Alanko T, Bono P.

Br J Cancer. 2011 Feb 15;104(4):599-604. doi: 10.1038/bjc.2011.2. Epub 2011 Feb 8.

3.

[Efficacy of chemotherapy combined with bevacizumab for metastatic colorectal cancer].

Momoi A, Motomura S, Hashimoto C, Takasaki H, Takemura S, Takagi S, Akaike M.

Gan To Kagaku Ryoho. 2011 Jan;38(1):79-83. Japanese.

PMID:
21368462
4.

Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients.

Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y.

Int J Clin Oncol. 2009 Dec;14(6):513-7. doi: 10.1007/s10147-009-0911-6. Epub 2009 Dec 5.

PMID:
19967487
5.

[Feasibility of bevacizumab for elderly patients with metastatic colorectal cancer].

Tsuchida K, Asari M, Numata K, Yoshida T, Osaragi T, Yoneyama K, Kasahara A, Yamamoto Y, Rino Y, Masuda M.

Gan To Kagaku Ryoho. 2012 Sep;39(9):1379-83. Japanese.

PMID:
22996773
6.

Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.

De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1207-13. doi: 10.1007/s00280-011-1604-1. Epub 2011 Mar 16.

PMID:
21409384
7.

[Second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer after resection of the primary lesion].

Abe H, Mafune K, Minamimura K, Abe M, Umemura A, Hirata T.

Gan To Kagaku Ryoho. 2013 May;40(5):601-4. Japanese.

PMID:
23863581
8.

Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.

Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, Dong W, Sugrue MM, Grothey A; Investigators of the BRiTE study.

Oncologist. 2009 Sep;14(9):862-70. doi: 10.1634/theoncologist.2009-0071. Epub 2009 Sep 2.

9.

[Clinical impact of addition of bevacizumab to the first-line chemotherapy regimen in the treatment of patients with metastatic colorectal cancer].

Sogabe S, Tateno T, Yagisawa M, Ishikawa M, Sawada K, Muranaka T, Umemura M, Kato R, Takasaka T, Takahashi K, Dazai M, Iwanaga I, Oda H, Miyagishima T.

Gan To Kagaku Ryoho. 2014 Sep;41(9):1113-7. Japanese.

PMID:
25248894
10.

Efficacy and toxicity of bevacizumab on combination with chemotherapy in different lines of treatment for metastatic colorectal carcinoma.

Kiss I, Bortlicek Z, Melichar B, Poprach A, Halamkova J, Vyzula R, Dusek L, Buchler T.

Anticancer Res. 2014 Feb;34(2):949-54.

PMID:
24511038
11.

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.

Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P.

BMC Cancer. 2009 Sep 28;9:347. doi: 10.1186/1471-2407-9-347.

12.

[Efficacy of chemotherapy combined with bevacizumab for unresectable advanced or recurrent colorectal cancer].

Watanabe T, Nishiwaki N, Kajiwara Y, Okamoto T, Miyamoto M, Kohjima T, Watanabe Y, Yoshino K, Kawai T, Toda K, Nobuhisa T, Endo Y, Matsumoto Y, Watanabe N, Kai K, Sato S.

Gan To Kagaku Ryoho. 2013 Jan;40(1):71-4. Japanese.

PMID:
23306921
13.

Retrospective study as first-line chemotherapy combined anti-VEGF antibody with fluoropyrimidine for frail patients with unresectable or metastatic colorectal cancer.

Yoshida M, Goto M, Kii T, Nishitani H, Kawabe S, Kuwakado S, Asaishi K, Miyamoto T, Higuchi K.

Digestion. 2013;87(1):59-64. doi: 10.1159/000343943. Epub 2013 Jan 21.

14.

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.

Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F.

J Clin Oncol. 2005 May 20;23(15):3502-8.

PMID:
15908660
15.

An open-label safety study of first-line bevacizumab in combination with standard chemotherapy in Chinese patients with metastatic colorectal cancer treated in an expanded access program in Taiwan.

Lee KD, Chen HH, Wang HM, Tsao CJ, Hsu TC, Chiu CF, Su WC, Wang JY.

Oncology. 2013;84(5):299-304. doi: 10.1159/000347228. Epub 2013 Mar 16.

PMID:
23548831
16.

Safety and tolerability of first-line bevacizumab in metastatic colorectal cancer.

Akun E, Okutur K, Seber S, Korkmaz T, Aydin K, Bozkurt M, Namal E, Hasbal B, Tecimer C, Demir G.

J BUON. 2012 Oct-Dec;17(4):669-76.

PMID:
23335523
17.

Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.

Takii Y, Maruyama S.

Chemotherapy. 2013;59(2):79-84. doi: 10.1159/000350497. Epub 2013 Jul 19.

PMID:
23881273
18.

Chemotherapy with bevacizumab for metastatic colorectal cancer: a retrospective review of 181 Japanese patients.

Saito S, Hayashi N, Sato N, Iwatsuki M, Baba Y, Sakamoto Y, Miyamoto Y, Watanabe M, Yoshida M, Sakai K, Katsumori T, Katahuchi S, Shigaki N, Yamada K, Kimura M, Tanigawa T, Takano S, Kuramoto M, Baba H.

Int J Clin Oncol. 2013 Aug;18(4):689-95. doi: 10.1007/s10147-012-0426-4. Epub 2012 Jun 5.

PMID:
22664951
19.

Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.

Kesmodel SB, Ellis LM, Lin E, Chang GJ, Abdalla EK, Kopetz S, Vauthey JN, Rodriguez-Bigas MA, Curley SA, Feig BW.

J Clin Oncol. 2008 Nov 10;26(32):5254-60. doi: 10.1200/JCO.2008.17.7857. Epub 2008 Oct 14.

PMID:
18854565
20.

[Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].

Koyama M, Murata A, Kimura Y, Sakamoto Y, Morohashi H, Kimura N, Gasa F, Sato J, Terui K, Awatsu A, Hakamada K.

Gan To Kagaku Ryoho. 2010 Jun;37(6):1069-73. Japanese.

PMID:
20567110

Supplemental Content

Support Center